These drugs, such as Enbrel, Stelara, Eliquis, Xarelto, Entresto, Imbruvica, Farxiga and many insulins, have list prices as ...

A new study shows that the US is still behind in controlling the price of prescription drugs. One doctor explains why America ...

French drugmaker Sanofi plans to change its policy on how it gives discounts to certain U.S. hospitals that serve low-income ...

A key provision of the Inflation Reduction Act (IRA) of 2022 directed Medicare to negotiate the prices of certain top-selling ...

Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances next year.

for ophthalmic diseases and anticoagulant Xarelto (rivaroxaban) in the coming years. Nubeqa is one of three drugs that the company is hoping will help it weather that impact on revenues ...

A new lawsuit over how pharmaceutical companies can dole out drug discounts to providers amplifies ... implement a new reimbursement model for Xarelto and Stelara starting in mid-October.

On Aug. 23, J&J announced a new rebate model it would implement for two drugs (psoriasis treatment Stelara and blood thinner Xarelto) only at Disproportionate Share Hospitals. The new J&J model ...

accusing the agency of blocking its plan to sell its psoriasis treatment Stelara and blood thinner Xarelto to some hospitals at full price before applying drug rebates. The 340B program has been ...

accuses the agency of blocking its plan to sell its psoriasis treatment Stelara and blood thinner Xarelto to some hospitals at full price before applying drug rebates. The 340B program ...